Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

View Full Paper
Ask AI
Bookmark
Share

Authors

WHWalter HanelJBJonathan E. BrammerLALapo Alinari

Discussion

Loading...

Member takes

Overview

Phase Ib trial indicates epcoritamab improves progression free survival in relapsed post-transplant lymphoproliferative disorder, suggesting potential for future combination therapies.

Key Points

  • Epcoritamab improved progression free survival in relapsed post-transplant lymphoproliferative disorder patients while showing manageable safety.
  • The trial includes adult patients with CD20-positive B-cell PTLD who previously failed chemoimmunotherapy or rituximab.
  • Assessment of the bi-specific antibody's safety and efficacy employs a phase Ib trial design with dose de-escalation strategies.
  • Research highlights the need for further exploration of epcoritamab's impact on the tumor microenvironment and Epstein-barr virus in PTLD.

Cite This Study

Hanel et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e32fhttps://doi.org/10.1182/blood-2025-8240
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial2025
  2. 2Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025
  3. 3Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma2025
  4. 4Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma2025 · 1 citations
  5. 5Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress2025